NeoStem Inc  

(Public, NASDAQ:NBS)   Watch this stock  
Find more results for David Liter�
6.46
-0.20 (-3.00%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.40 - 6.66
52 week 5.00 - 9.89
Open 6.57
Vol / Avg. 331,896.00/333,499.00
Mkt cap 184.64M
P/E     -
Div/yield     -
EPS -1.91
Shares 28.58M
Beta 1.43
Inst. own 14%
May 12, 2014
Q1 2014 NeoStem Inc Earnings Release - 4:00PM EDT - Add to calendar
Apr 30, 2014
NeoStem Inc at Thomson Reuters ALLICENSE CONFERENCE - 12:10PM EDT - Add to calendar
Apr 14, 2014
NeoStem Inc to Acquire California Stem Cell, Inc.
Mar 28, 2014
NeoStem Inc at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference
Mar 26, 2014
NeoStem Inc at Alliance for Regenerative Medicine RegenMed Investor Day
Mar 26, 2014
NeoStem Inc at Alliance for Regenerative Medicine RegenMed Investor Day (Cardiovascular Disease Panel)
Mar 13, 2014
Q4 2013 NeoStem Inc Earnings Release
Mar 3, 2014
NeoStem Inc at Cowen Health Care Conference
Mar 3, 2014
NeoStem Inc at The Wall Street Analyst Investor Conference
Feb 18, 2014
NeoStem Inc at RRY Publications Stem Cell Summit
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -311.87% -269.19%
Operating margin -257.33% -250.94%
EBITD margin - -239.99%
Return on average assets -69.12% -54.76%
Return on average equity -102.35% -81.45%
Employees 108 -
CDP Score - -

Address

SUITE 450, 420 LEXINGTON AVENUE
NEW YORK, NY 10170
United States - Map
+1-212-5844171 (Phone)
+1-646-5147787 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NeoStem, Inc. operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�s business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�s wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing.

Officers and directors

Robin L. Smith M.D. Chairman of the Board, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Robert IV Dickey IV Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Robert A. Preti Ph.D. President and Chief Scientific Officer - PCT
Age: 56
Bio & Compensation  - Reuters
Jeff Liter Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Stephen W. Potter Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Joseph Talamo Vice President, Chief Accounting Officer, Corporate Controller
Age: 43
Bio & Compensation  - Reuters
Catherine M. Vaczy Esq Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
David Altarac Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Timothy Fong PhD. Vice President
Age: 55
Bio & Compensation  - Reuters
Lawrence A. May M.D. Vice President - Strategic Initiatives
Age: 63
Bio & Compensation  - Reuters